Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Astellas Pharma Global Development, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1

Not yet recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: ASP2138
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-FU
Drug: Irinotecan
Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Capecitabine

First Posted Date: 2025-06-17

Last Posted Date: 2025-06-17

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 25

Registration Number: NCT07024615

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Metastatic Hormone Sensitive Prostate Cancer

Interventions: Drug: ASP5541
Drug: Prednisone
Drug: Prednisolone
Drug: abiraterone acetate

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 218

Registration Number: NCT07005154

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Phase 3

Recruiting

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: zolbetuximab
Drug: Pembrolizumab
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Folinic acid (leucovorin or local equivalent)
Drug: 5-fluorouracil (5-FU)
Drug: Placebo

First Posted Date: 2025-03-30

Last Posted Date: 2025-06-18

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 500

Registration Number: NCT06901531

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4

Not yet recruiting

Conditions: Metastatic Urothelial Carcinoma

Interventions: Drug: Enfortumab Vedotin

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 100

Registration Number: NCT06862219

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

Phase 2

Recruiting

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Placebo

First Posted Date: 2025-02-06

Last Posted Date: 2025-06-29

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 150

Registration Number: NCT06812754

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Capital Medical University (CMU) - Beijing Shijitan Hospital, Beijing, Beijing, China

and more 23 locations

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Recruiting

Conditions: Geographic Atrophy
Macular Degeneration

Interventions: Drug: Avacincaptad pegol (ACP)

First Posted Date: 2025-01-17

Last Posted Date: 2025-06-27

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 1000

Registration Number: NCT06779773

Locations: 🇺🇸
Retinal Consultants Medical Group Inc, Sacramento, California, United States
🇺🇸
Colorado Retina Associates, PLLC, Lakewood, Colorado, United States
🇺🇸
Illinois Retina Associates, Oak Park, Illinois, United States

and more 23 locations

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Phase 1

Withdrawn

Conditions: Testicular Cancer
CLDN6-positive Solid Tumor
Ovarian Cancer
Endometrial Cancer
Metastatic or Locally Advanced Solid Tumor Cancer
Non-small Cell Lung Cancer

Interventions: Drug: ASP1893

First Posted Date: 2024-11-08

Last Posted Date: 2025-01-15

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 197

Registration Number: NCT06681870

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Phase 1

Recruiting

Conditions: Healthy Volunteers
Sjögren's Syndrome

Interventions: Drug: ASP5502
Drug: Placebo

First Posted Date: 2024-08-09

Last Posted Date: 2025-05-08

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 132

Registration Number: NCT06544642

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc, Daytona Beach, Florida, United States

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Completed

Conditions: Prostate Cancer

Interventions: Other: No Intervention

First Posted Date: 2024-07-15

Last Posted Date: 2025-05-06

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 374

Registration Number: NCT06500741

Locations: 🇺🇸
Analysis Group, Inc., Boston, Massachusetts, United States

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 3

Recruiting

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Placebo
Drug: Tamoxifen
Drug: Aromatase inhibitor

First Posted Date: 2024-06-04

Last Posted Date: 2025-06-29

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 540

Registration Number: NCT06440967

Locations: 🇨🇦
Site CA15002, Montreal, Quebec, Canada
🇨🇦
Site CA15001, Quebec City, Quebec, Canada
🇨🇦
Site CA15003, Sherbrooke, Quebec, Canada

and more 76 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy